Short bowel syndrome - Teduglutide (Revestive®)

10/04/2018

Updates on the approval for Tedgulutide (Revestive®) in England and Scotland.

Important notes for members:

  • Tedgulutide (Revestive®) is the same product as some may have read about on social media - Gattex ®
  • It is being used in other countries and the results are encouraging.
  • The pharmaceutical company cannot deal or respond directly to individual patients.
  • The requirements for use are very specific; if you are keen to find out more ask your own healthcare professionals.
  • PINNT is a registered stakeholder and has consulted on the product giving the patient/carer feedback. We continue to thank PINNT members who took part in our survey, this information has proved vital for us to give genuine experiences of life with SBS-IF/Home Artificial Nutrition.
  • This is one product; others will follow - PINNT will continue to present the users perspective. We thank members who have taken part in various surveys to help the enquiries we receive when approached by agencies who want to speak directly to patients and carers. 

__________________________________________________________________________________

The Scottish Medicines Consortium (SMC)

The SMC completed an assessment of the product. Their decision regarding Teduglutide (Revestive®) was published on 9th April 2018. The relevant Detailed Advice Document can be found here.
__________________________________________________________________________________

NICE - England: the process is under way, it is currently seeking new evidence for review and will refer back to the consultees when the process continues or is recommenced.
__________________________________________________________________________________

It's now closed - thanks to those who submitted comments via the official channel. We appreciated feedback from you to PINNT; we hope to retain our valuable input during this process.


The consultation is now open - your support could influence the outcome!
The deadline for comments is 4th December 2017 - 5.00pm


The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using teduglutide in the NHS in England. The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees and commentators, clinical experts and patient experts.

We, PINNT, were able to use our Short Bowel Syndrome Survey (SBS) results to represent life with SBS/IF/HPN. 

It's now time for you to comments on the outcome of the appraisal. 

The appraisal committee is interested in receiving comments on the following:

·      Has all of the relevant evidence been taken into account?

·      Are the summaries of clinical & cost effectiveness reasonable interpretations of the evidence?

·      Are the recommendations sound and a suitable basis for guidance to the NHS?

·      Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?

You can comment on this appraisal - to do this use this linkhttps://www.nice.org.uk/guidance/in development/gid-ta10048/consultation/html-content 

You will then need to log in if you have an account or set one up before being able to comment.

You must read the Appraisal Consultation Document https://www.nice.org.uk/guidance/GID-TA10048/documents/appraisal-consultation-document​ having done so you can then submit your comments.



Back

Latest News